Immunogenicity of hepatitis B surface antigen derived from the baculovirus expression vector system: a mouse potency study

Roberta Attanasio, Robert E. Lanford, Dennis Dilley, Gregory W. Stunz, Lena Notvall, A. Burl Henderson, Ronald C. Kennedy

    Research output: Contribution to journalArticlepeer-review

    3 Scopus citations

    Abstract

    A standard mouse potency test was performed to evaluate the immunogenicity of recombinant hepatitis B surface antigen (HBsAg) produced in the baculovirus/insect cell expression system. Groups of NIH Swiss mice were immunized with serial four-fold amounts of either baculovirus-derived HBsAg adsorbed to aluminum sulfate or a commercially available yeast-derived recombinant HBsAg vaccine preparation. Results from these experiments showed that the effective dose of baculovirus-and yeast-derived HBsAg vaccine preparations necessary to seroconvert 50% of the animals were similar. The duration of the antibody response to HBsAg was studied in mice immunized with the highest doses of the two recombinant vaccine preparations 3 and 6 months after injection. No decrease in the anti-HBs response was observed 6 months after injection. No decrease in the anti-HBs response was observed 6 months after immunization with either of the two vaccine preparations. These results indicate that the baculovirus-derived recombinant HBsAg could serve as an alternative vaccine candidate for hepatitis B virus.

    Original languageEnglish (US)
    Pages (from-to)347-353
    Number of pages7
    JournalBiologicals
    Volume19
    Issue number4
    DOIs
    StatePublished - Oct 1991

    ASJC Scopus subject areas

    • Biotechnology
    • Bioengineering
    • Applied Microbiology and Biotechnology
    • Immunology and Microbiology(all)
    • Pharmacology

    Fingerprint Dive into the research topics of 'Immunogenicity of hepatitis B surface antigen derived from the baculovirus expression vector system: a mouse potency study'. Together they form a unique fingerprint.

    Cite this